Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

8GFA

Cryo-EM structure of human TRPV1 in complex with the analgesic drug SB-366791

8GFA の概要
エントリーDOI10.2210/pdb8gfa/pdb
関連するPDBエントリー8GF8 8GF9
EMDBエントリー29981 29982 29983
分子名称Transient receptor potential cation channel subfamily V member 1, (2S)-3-(hexadecanoyloxy)-2-[(9Z)-octadec-9-enoyloxy]propyl 2-(trimethylammonio)ethyl phosphate, (2E)-3-(4-chlorophenyl)-N-(3-methoxyphenyl)prop-2-enamide, ... (6 entities in total)
機能のキーワードtransient receptor potential v family member 1, trp, human, channel, inhibition, antagonist, trpv1, trp channels, pain, analgesic, drug, membrane protein, sb-366791, thermo-trp, temperature sensation, vanilloid, gdn, detergent, glyco-diosgenin
由来する生物種Homo sapiens (human)
タンパク質・核酸の鎖数4
化学式量合計528927.81
構造登録者
Neuberger, A.,Nadezhdin, K.D.,Sobolevsky, A.I. (登録日: 2023-03-07, 公開日: 2023-05-10, 最終更新日: 2024-10-23)
主引用文献Neuberger, A.,Oda, M.,Nikolaev, Y.A.,Nadezhdin, K.D.,Gracheva, E.O.,Bagriantsev, S.N.,Sobolevsky, A.I.
Human TRPV1 structure and inhibition by the analgesic SB-366791.
Nat Commun, 14:2451-2451, 2023
Cited by
PubMed Abstract: Pain therapy has remained conceptually stagnant since the opioid crisis, which highlighted the dangers of treating pain with opioids. An alternative addiction-free strategy to conventional painkiller-based treatment is targeting receptors at the origin of the pain pathway, such as transient receptor potential (TRP) ion channels. Thus, a founding member of the vanilloid subfamily of TRP channels, TRPV1, represents one of the most sought-after pain therapy targets. The need for selective TRPV1 inhibitors extends beyond pain treatment, to other diseases associated with this channel, including psychiatric disorders. Here we report the cryo-electron microscopy structures of human TRPV1 in the apo state and in complex with the TRPV1-specific nanomolar-affinity analgesic antagonist SB-366791. SB-366791 binds to the vanilloid site and acts as an allosteric hTRPV1 inhibitor. SB-366791 binding site is supported by mutagenesis combined with electrophysiological recordings and can be further explored to design new drugs targeting TRPV1 in disease conditions.
PubMed: 37117175
DOI: 10.1038/s41467-023-38162-9
主引用文献が同じPDBエントリー
実験手法
ELECTRON MICROSCOPY (2.29 Å)
構造検証レポート
Validation report summary of 8gfa
検証レポート(詳細版)ダウンロードをダウンロード

246905

件を2025-12-31に公開中

PDB statisticsPDBj update infoContact PDBjnumon